Form 4: Esperion Legal Chief Sells Shares for Tax Obligation
Insider Transaction Report
Esperion Therapeutics' Chief Legal Officer, Benjamin Looker, sold 5,708 shares of common stock to cover tax obligations on vested restricted stock units.
Summary
- Benjamin Looker, Chief Legal Officer of Esperion Therapeutics, Inc. (ESPR), sold 5,708 shares of common stock.
- The transaction occurred on March 17, 2026, at a price of $2.703 per share.
- The sale was conducted to satisfy tax obligations arising from the vesting of restricted stock units.
- Following this transaction, Benjamin Looker directly beneficially owns 679,348 shares of Esperion Therapeutics common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine tax-related transaction, not a discretionary sale, and therefore does not signal a change in insider sentiment regarding the company's future.
Positives
- The transaction is a routine sale to cover tax obligations, indicating a pre-planned event rather than a discretionary sale based on market sentiment.
Negatives
- A reduction in insider ownership, even for tax purposes, slightly decreases the alignment of the officer's direct equity interest with shareholders.
Risks
- No specific risks are mentioned in the filing beyond the routine nature of the transaction.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that sales of shares to cover tax obligations on vested restricted stock units are a common and routine occurrence for executives, often pre-arranged under Rule 10b5-1 plans. This type of transaction is generally not indicative of a change in management's outlook on the company's prospects but rather a standard compensation and tax management practice.
Comparison to Industry Standards
- NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | Benjamin Looker granted a Limited Power of Attorney to Sheldon Koenig and Richard Bartram to execute and file SEC forms (Form ID, 3, 4, 5, Schedule 13D) on his behalf. | 2021-12-13 | This is a standard administrative arrangement to facilitate timely and compliant SEC filings for the officer, ensuring adherence to Section 16 reporting requirements. |
Stakeholder Impact
- Shareholders: A minor reduction in direct insider ownership, but the routine nature of the sale minimizes negative implications.
- Employees: No direct impact on employees.
- Customers: No direct impact on customers.
- Suppliers: No direct impact on suppliers.
- Creditors: No direct impact on creditors.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2021-12-13 | Effective date of the Limited Power of Attorney granted by Benjamin Looker. |
| 2026-03-17 | Date of common stock transaction (sale of shares). |
| 2026-03-18 | Date the Form 4 was signed and filed. |
Recommendation
holdThe filing details a routine, non-discretionary sale of shares by an executive to cover tax obligations. This type of transaction is common and does not typically reflect a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.
Keywords
Esperion Therapeutics, ESPR, Form 4, Insider Trading, Stock Sale, Tax Obligation, Restricted Stock Units, Benjamin Looker, Chief Legal Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.